Biopharmaceutical company Starpharma revealed on Wednesday that the SPL7013 agent in VIRALEZE nasal spray has a strong virucidal effect against the worldwide delta variant of SARS-CoV-2 and reduces its infectivity by> 99.99% after 30 seconds of exposure in laboratory-based virucidal assays.
Based on laboratory studies, SPL7013, the antiviral agent in VIRALEZE , has now been shown to be virucidal against all four coronaviruses SARS-CoV-2: Alpha, Beta, Gamma and Delta. The antiviral effects of SPL7013 cover a broad spectrum and effective against several respiratory viruses including influenza and RSV, as well as its consistent and potent activity against several SARS-CoV-2 variants.
SPL7013's antiviral testing was performed in the lab of virologist Professor Philippe Gallay at the Scripps Research Institute in the US, where previous studies have shown SPL7013's potent antiviral and virucidal activity against several variants of SARS-CoV-2, including those used worldwide Alpha , beta and gamma variants classified as "Variant of Interest".
The VIRALEZE nasal antiviral spray is approved for sale in Europe and India and is available online in certain markets.
In addition, the Delta variant is reported to be about 60% more transmissible than the already highly infectious Alpha variant and is now the most common variant in India and the UK, where it accounts for more than 90% of new cases, concluded the company.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients